Antibacterial hemostatic material and preparation method thereof

By generating a low-temperature gel sponge with crosslinked phosphate groups, combining polyphosphate substances and mesoporous bioactive glass, the shortcomings of existing hemostatic materials in acute bleeding and antibacterial properties are solved, and rapid hemostatic and antibacterial effects are achieved. Significantly shortens bleeding time and displays efficient coagulation and antibacterial properties.

CN118903531APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410959254.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing hemostatic materials are difficult to stop bleeding quickly and effectively in the case of acute bleeding, and lack antibacterial properties, which can easily lead to infection.

Method used

Polyphosphate reacts with nitrogen-containing heterocyclic compounds to form polyphosphate substances, combines methacrylylated gelatin and mesoporous bioactive glass to form a low-temperature gel sponge with crosslinked phosphate groups, which is porous to accommodate blood components It also contains antibacterial metal ions and tannins, which promote coagulation and antibacterial effects.

Benefits of technology

It achieves significant hemostasis and antibacterial properties, can quickly adhere to the bleeding wound to promote fibrin mesh formation, shorten bleeding time, and show efficient coagulation index and antibacterial effects in in vitro and in vivo testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004949810070000011
    Figure HDA0004949810070000011
  • Figure HDA0004949810070000012
    Figure HDA0004949810070000012
  • Figure HDA0004949810070000021
    Figure HDA0004949810070000021
Patent Text Reader

Abstract

The invention belongs to the technical field of medical materials, and particularly relates to an antibacterial hemostatic material and a preparation method thereof. Compared with the prior art, the antibacterial hemostatic material prepared by the invention is a low-temperature gel sponge containing a cross-linked phosphate group, has porosity and can contain various components of blood, and the material niche can provide adhesion sites for soluble and insoluble elements in the blood, such as red blood cells, platelets and fibrinogen; a sponge pore chamber contains rich phosphate groups, so that an adhesion position can be provided to prevent blood from flowing; and along with the increase of the concentration of various blood coagulation components in the material niche, the generation of a blood coagulation reaction is facilitated, so that the antibacterial hemostatic material has remarkable hemostatic capability and antibacterial performance, can be adhered to injured tissues of a bleeding wound surface, promotes the formation of a fibrous protein net, and shortens the bleeding time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical materials, and in particular relates to an antibacterial hemostatic material and a preparation method thereof. Background Art

[0002] The skin isolates the internal environment from the external environment. It is the largest and most important immune organ in the human body and has made outstanding contributions to protecting the stability of the internal environment and maintaining normal cell growth and metabolism. Fatal uncontrollable acute bleeding in patients with trauma, surgery, and bone marrow failure is a great threat to human life and health. In addition to acute bleeding caused by trauma, disease-related bleeding complications are also a major factor leading to early death. For example, bleeding is an important clinical manifestation of acute promyelocytic leukemia (AML) and aplastic anemia (AA). Spontaneous persistent nosebleeds caused by coagulation disorders in patients with malignant blood diseases increase the risk of infection, and complications caused by the disease significantly reduce the quality of life of patients. Although replacement therapy is currently the treatment method for congenital coagulopathy (such as hemophilia), there are also reports of treatment with advanced materials. Replacement transfusion is a widely accepted principle of blood management, including the transfusion of various blood components, such as platelets, fresh virus-inactivated plasma, and recombinant coagulation factor VII. However, in the current situation of blood product shortage, there is an urgent need to design hemostatic agents to meet clinical needs for acute and chronic bleeding.

[0003] The risk of bleeding and infection increases when suffering from hematologic malignancies. For example, patients with acute myeloid leukemia are susceptible to bacterial and fungal infections due to granulocyte dysfunction and quantitative defects. Lymphocyte quality defects, hypoglobulinemia, and reduced cell-mediated immunity caused by acute lymphoblastic leukemia make patients susceptible to bacterial, fungal, and viral invasion. Treatment with hematopoietic stem cell transplantation in the setting of chemotherapy for hematologic malignancies and myeloablative therapy often results in a persistent decrease in granulocytes and damage to the mucosal barrier, leading to oral mucositis, which further increases the risk of infection.

[0004] With the advancement of materials science, the progress of hemostatic materials is the result of multiple iterations of new and old ideas. Some classic hemostatic agents come from various natural and artificial hemostatic materials, such as zeolites, mesoporous silica, hydrogels, tourniquets, and gauze. One of the main challenges of hemostatic materials is to avoid the leakage of hemostatic active substances from the wound area, especially when using nanocomposite hemostatic agents. The emergence of smart photocrosslinked hydrogels provides various possibilities for wound control. However, considering the potential damage to local tissues using ultraviolet light crosslinking limits its scope of application. And in cases where sudden hemostasis is required, collateral damage caused by unskilled operation is inevitable. In addition, the synthesis of these materials requires complex procedures and is costly in terms of commercial and clinical product development.

[0005] Gelatin is a collagen derivative with low immunogenicity and can be modified to incorporate side groups, such as methacrylate hydrogel (GelMA). Hydrogels are widely adopted as the first choice for medical wound dressings due to their excellent tissue compatibility, cross-linked networks, and abundant functional groups. However, previous hydrogels have mainly focused on the adhesion properties for wound closure and repair, while ignoring local platelet activation and the formation of local fibrin networks. When considering the design of hemostatic hydrogels for coagulation and achieving rapid hemostasis in critical situations, rapid in situ gelation is one of the main factors to be considered, which ensures that the gel does not spread away from the bleeding site. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide an antibacterial hemostatic material with significant hemostatic ability and antibacterial properties and a preparation method thereof.

[0007] The present invention provides a method for preparing an antibacterial hemostatic material, comprising the following steps:

[0008] S1) reacting phosphate with a nitrogen-containing heterocyclic compound in the presence of a coupling agent to obtain a polyphosphoric acid substance containing a nitrogen-containing heterocyclic ring;

[0009] S2) mixing the polyphosphoric acid substance containing nitrogen-containing heterocycles with methacryloyl gelatin to obtain phosphorylated modified methacryloyl gelatin;

[0010] S3) mixing the phosphorylated modified methacryloyl gelatin, an initiator and a cross-linking agent in water, gelling at low temperature, and freeze-drying to obtain a phosphoric acid-modified cryogel;

[0011] S4) co-incubating the phosphoric acid-modified cryogel with mesoporous bioactive glass in an aqueous phase to obtain an antibacterial hemostatic material; the mesoporous bioactive glass contains antibacterial metal ions and / or tannic acid.

[0012] Preferably, the mesoporous bioactive glass is prepared according to the following method:

[0013] A1) mixing an antibacterial metal ion with ascorbic acid under heating to obtain a metal / ascorbic acid mixed solution;

[0014] A2) mixing the template solution with an organic solvent, then adding a precipitant and mixing, and then adding a silicon source, a calcium source and a metal / ascorbic acid mixed solution, reacting, drying, and calcining to obtain a metal ion-containing bioactive glass;

[0015] A3) Soaking the metal ion-containing bioactive glass in a tannic acid solution and freeze-drying the solution to obtain the mesoporous bioactive glass.

[0016] Preferably, the metal ions having antibacterial properties are selected from copper ions;

[0017] The template in the template solution is selected from long-chain quaternary ammonium salts;

[0018] The organic solvent is selected from ethyl acetate;

[0019] The precipitant is selected from ammonia water;

[0020] The silicon source is selected from alkyl silicates;

[0021] The calcium source is selected from calcium nitrate.

[0022] Preferably, the molar ratio of the antibacterial metal ion to ascorbic acid is 1:(1-4);

[0023] The volume of the organic solvent is 0.01% to 0.05% of the volume of the template solution;

[0024] The molar ratio of the template, the precipitant, the silicon source and the calcium source in the template solution is (1-2): (4-8): (10-15): (10-15);

[0025] The molar ratio of the silicon source to the metal ions in the metal / ascorbic acid mixed solution is (10-15): (0.5-1);

[0026] The mass concentration of tannic acid in the tannic acid solution is 1% to 10%.

[0027] Preferably, the step A1) is specifically as follows: heating an aqueous solution of antibacterial metal ions, then dropping an ascorbic acid solution, heating and mixing, and centrifuging to obtain a metal / ascorbic acid mixed solution; the temperatures of the heating and heating mixing are independently 70°C to 90°C; and the heating and mixing time is 20 to 30 hours.

[0028] Preferably, the time for mixing the template solution and the organic solvent in step A2) is 20 to 40 minutes;

[0029] The mixing time of adding precipitant is 10 to 20 minutes;

[0030] The interval between adding silicon source and calcium source is 10 to 50 minutes;

[0031] The reaction time is 2 to 6 hours;

[0032] The calcination temperature is 500°C to 900°C; the calcination time is 2 to 6 hours;

[0033] The soaking time in step A3) is 6 to 12 hours.

[0034] Preferably, the phosphate is selected from sodium hexametaphosphate;

[0035] The nitrogen-containing heterocyclic compound is selected from imidazole;

[0036] The molar ratio of the phosphate to the nitrogen-containing heterocyclic compound is (8-20):1;

[0037] The mass ratio of the polyphosphoric acid substance containing nitrogen-containing heterocyclic ring to the methacrylated gelatin is 1:(5-15);

[0038] The initiator is selected from ammonium persulfate and / or potassium persulfate;

[0039] The cross-linking agent is selected from tetramethylethylenediamine;

[0040] The temperature of the low-temperature gelling is -10°C to -30°C; the time of the low-temperature gelling is 15 to 30 hours;

[0041] The freeze-drying temperature in step S3) is -60°C to -100°C, the pressure is 0.0005 to 0.002 mbar, and the time is 1 to 5 days.

[0042] Preferably, the step S4) is specifically as follows: ultrasonically dispersing the mesoporous bioactive glass in water, then adding phosphoric acid-modified cryogel for co-incubation, and freeze-drying to obtain the antibacterial hemostatic material.

[0043] Preferably, the ratio of the mesoporous bioactive glass to water in step S4) is (0.1-1) mg:1 mL;

[0044] The power of ultrasonic dispersion in step S4) is 100-300W; the time of ultrasonic dispersion is 10-50min;

[0045] The co-incubation time is 6 to 12 hours;

[0046] The freeze-drying temperature in step S4) is -60°C to -100°C, the pressure is 0.0005 to 0.002 mbar, and the time is 1 to 5 days.

[0047] The present invention also provides an antibacterial hemostatic material prepared by the above preparation method.

[0048] The invention provides a method for preparing an antibacterial hemostatic material, comprising the following steps: S1) reacting phosphate with a nitrogen-containing heterocyclic compound in the presence of a coupling agent to obtain a polyphosphate substance containing a nitrogen-containing heterocyclic ring; S2) mixing the polyphosphate substance containing a nitrogen-containing heterocyclic ring with methacryloyl gelatin to obtain phosphorylated modified methacryloyl gelatin; S3) mixing the phosphorylated modified methacryloyl gelatin, an initiator and a cross-linking agent in water, gelling at low temperature, and freeze-drying to obtain a phosphoric acid-modified cryogel; S4) co-incubating the phosphoric acid-modified cryogel with a mesoporous bioactive glass in an aqueous phase to obtain an antibacterial hemostatic material; the mesoporous bioactive glass contains antibacterial metal ions and / or tannic acid. Compared with the prior art, the antibacterial hemostatic material prepared by the present invention is a low-temperature gel sponge containing cross-linked phosphate groups, which is porous and can accommodate various components of blood. The material niche can provide adhesion sites for soluble and insoluble elements in the blood, including red blood cells, platelets and fibrinogen, and the sponge pore chamber contains abundant phosphate groups, which can provide adhesion positions to prevent blood flow; and as the concentration of various coagulation components in the material niche increases, it is conducive to promoting the occurrence of coagulation reaction, so that the antibacterial hemostatic material has significant hemostatic ability and antibacterial properties, can adhere to the damaged tissue of the bleeding wound, promote the formation of fibrin network, and thus shorten the bleeding time.

[0049] Furthermore, the present invention verifies the potential for application in diseases by measuring the coagulation index of the antibacterial hemostatic material in vitro to evaluate the coagulation efficiency, and performing hemostasis tests in a rat liver injury bleeding model, aplastic anemia model mouse, and amputation and tail bleeding tests in a hemophilia model mouse. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 Schematic diagram of the synthesis steps of the phosphoric acid-modified cryogel loaded with bioactive glass containing tannic acid and copper ions according to the present invention;

[0051] Figure 2 is a photograph of the cryogel obtained in the examples of the present invention;

[0052] Figure 3 The morphological structure photos and characterization diagrams of the bioactive glass obtained in the examples of the present invention are shown;

[0053] Figure 4The SEM images of the cryogel obtained in the embodiment of the present invention at 200 times, 500 times, and 5000 times;

[0054] Figure 5 This is the nuclear magnetic resonance spectrum of the GP cryogel obtained in the example of the present invention;

[0055] Figure 6 is a swelling rate curve of GP@BG-Cu-TA cryogel obtained in an embodiment of the present invention;

[0056] Figure 7 Graph showing the porosity test results of the cryogel obtained in an embodiment of the present invention;

[0057] Figure 8 This is a graph showing the degradation rate of the cryogel obtained in an embodiment of the present invention;

[0058] Fig. 9 Live-dead staining images of each treatment group of cryogel obtained in the examples of the present invention and quantitative images of NIH3T3 live cell proliferation;

[0059] Fig.10 This is a result diagram showing the effect of the cryogel material extract obtained in the example of the present invention on the proliferation ability of NIH3T3 cells;

[0060] Fig.11 The colony photos and the quantitative graph of the colony number of the agarose bacterial culture dish coated with each group of cryogels after co-culture in the embodiment of the present invention;

[0061] Fig.12 This is a general photo of full-thickness healing in an embodiment of the present invention;

[0062] Fig.13 This is a statistical analysis diagram of full-thickness healing in an embodiment of the present invention;

[0063] Fig.14 This is a graph showing the test results of the cryogel in vitro coagulation index obtained in an embodiment of the present invention;

[0064] Fig.15 This is a schematic diagram of hemostasis in a rat liver injury model according to an embodiment of the present invention;

[0065] Fig.16 This is a graph showing the results of an in vivo compatibility study of the cryogel material obtained in an example of the present invention. DETAILED DESCRIPTION

[0066] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0067] The invention provides a method for preparing an antibacterial hemostatic material, comprising the following steps: S1) reacting phosphate with a nitrogen-containing heterocyclic compound in the presence of a coupling agent to obtain a polyphosphate substance containing a nitrogen-containing heterocyclic ring; S2) mixing the polyphosphate substance containing a nitrogen-containing heterocyclic ring with methacryloyl gelatin to obtain phosphorylated modified methacryloyl gelatin; S3) mixing the phosphorylated modified methacryloyl gelatin, an initiator and a cross-linking agent in water, gelling at low temperature, and freeze-drying to obtain a phosphoric acid-modified cryogel; S4) co-incubating the phosphoric acid-modified cryogel with a mesoporous bioactive glass in an aqueous phase to obtain an antibacterial hemostatic material; the mesoporous bioactive glass contains antibacterial metal ions and / or tannic acid.

[0068] The present invention has no particular limitation on the sources of all raw materials, and any raw materials available on the market can be used.

[0069] Phosphate and nitrogen-containing heterocyclic compound are reacted in the presence of a coupling agent to obtain a polyphosphoric acid substance containing nitrogen-containing heterocyclic ring; the phosphate can be any phosphate well known to those skilled in the art without any special limitation, and is preferably sodium hexametaphosphate in the present invention; the nitrogen-containing heterocyclic compound is preferably imidazole; the molar ratio of the phosphate to the nitrogen-containing heterocyclic compound is preferably (8-20):1, more preferably (10-15):1, and further preferably (13-14):1; the coupling agent can be any coupling agent well known to those skilled in the art without any special limitation, and is preferably EDC, CMC, DCC, DIC, NHS, Sluf o-NHS, MAL, NEM, SFB, TEMED and one or more of succinic anhydride; the reaction temperature is room temperature; the reaction time is 1.5 to 2 hours; after the reaction is completed, it is preferably purified by ethanol precipitation, and after freeze-drying, a polyphosphate substance containing nitrogen heterocycles is obtained; the freeze-drying temperature is preferably -60°C to -100°C, more preferably -70°C to -90°C, and more preferably -80°C, the pressure is preferably 0.0005 to 0.002 mbar, more preferably 0.0008 to 0.0015 mbar, and more preferably 0.001 mbar; the freeze-drying time is preferably 2 to 4 days, more preferably 3 days.

[0070] The polyphosphoric acid substance containing nitrogen-containing heterocycles is mixed with methacrylic gelatin to obtain phosphorylated modified methacrylic gelatin; the mass ratio of the polyphosphoric acid substance containing nitrogen-containing heterocycles to the methacrylic gelatin is preferably 1: (5-15), more preferably 1: (8-12), and more preferably 1: 10; the methacrylic gelatin can be methacrylic gelatin well known to those skilled in the art, and there is no special limitation. In the present invention, it is preferably prepared according to the following method: gelatin is dissolved in hot PBS solution, and then methacrylic anhydride is added under light-proof conditions to carry out acylation reaction, and after completion, preheated PBS solution is added, filtered, unreacted compounds are removed by dialysis, and methacrylic gelatin is obtained after freeze-drying; the freezing strength of the gelatin is preferably 150-300g bloom, and more preferably 200-250g bloom, and more preferably 250g bloom; the ratio of the gelatin to the PBS solution is preferably 1g: (5-15) mL, more preferably 1g: (8-12) mL, and more preferably 1g: 10 mL; the temperature of the hot PBS solution is preferably 50°C-70°C, more preferably 55°C-65°C, and more preferably 60°C; the ratio of the gelatin to methacrylic anhydride is preferably 1g: (0.5-1) mL, more preferably 1g: (0.7-0.9) mL, and more preferably 1g: 0.8 mL; the methacrylic anhydride is preferably added within 30-90 min, more preferably within 50-70 min, and more preferably within 60 min; the temperature of the preheated PBS solution is preferably 50°C-70°C, more preferably 55°C-65°C, and more preferably 60°C; the preheated PBS solution is preferably The volume ratio of the PBS solution to the hot PBS solution is preferably (2-5):1, more preferably (3-4):1, and more preferably 3:1; the filtration preferably uses a 0.22 μm filter membrane; the dialysis preferably uses a dialysis bag with a molecular weight cutoff of 8000-14000 Da; the dialysis is preferably performed in deionized water; the dialysis time is preferably 10-16 days, more preferably 12-16 days, and more preferably 14 days; during the dialysis process, the deionized water is preferably replaced twice a day; the freeze-drying temperature is preferably -60°C to -100°C, more preferably -70°C to -90°C, and more preferably -80°C; the pressure is preferably 0.0005-0.002 mbar, more preferably 0.0008-0.0015 mbar, and more preferably 0.001 mbar; the freeze-drying time is preferably 2-4 days, and more preferably 3 days.

[0071] In a specific embodiment provided by the present invention, methacrylic gelatin is dissolved in water to obtain a methacrylic gelatin solution; the methacrylic gelatin solution is mixed with a polyphosphoric acid substance containing a nitrogen-containing heterocycle to obtain phosphorylated modified methacrylic gelatin; the mass ratio of the methacrylic gelatin to water is preferably 0.001 to 0.1:1, more preferably 0.005 to 0.05:1, and even more preferably 0.01:1; the mixing reaction time is preferably 6 to 12 hours, more preferably 8 to 12 hours.

[0072] In a specific embodiment provided by the present invention, methacrylic gelatin is dissolved in water to obtain a methacrylic gelatin solution; the methacrylic gelatin solution is mixed with a polyphosphoric acid substance containing a nitrogen-containing heterocycle for reaction, and freeze-dried to obtain phosphorylated modified methacrylic gelatin; the freeze-drying temperature is preferably -60°C to -100°C, more preferably -70°C to -90°C, and more preferably -80°C; the pressure is preferably 0.0005 to 0.002 mbar, more preferably 0.0008 to 0.0015 mbar, and more preferably 0.001 mbar; the freeze-drying time is preferably 2 to 4 days, and more preferably 3 days.

[0073] The phosphorylated modified methacryloyl gelatin, an initiator and a cross-linking agent are mixed in water, subjected to low temperature gelation, and freeze-dried to obtain a phosphoric acid-modified cryogel; the initiator can be any initiator known to those skilled in the art without any special limitation, and in the present invention, ammonium persulfate and / or potassium persulfate are preferably used; the cross-linking agent is preferably tetramethylethylenediamine (TEMED); the mass ratio of the phosphorylated modified methacryloyl gelatin, the initiator and the cross-linking agent is preferably 100:(0.02-0.08):0.01, more preferably 100:(0.04-0.06):0.01, and more preferably 100:0.05:0.01; the temperature of the low temperature gelation is preferably -10°C to -30°C, more preferably -15°C to -25°C, and more preferably -20℃; the time of low-temperature gelation is preferably 15-30h, more preferably 18-26h, more preferably 20-26h, and most preferably 24h; after low-temperature gelation, it is preferably thawed at room temperature, then washed with water to remove unreacted compounds, and then freeze-dried; the number of water washings is preferably 2-4 times, more preferably 3 times; the water washing is preferably carried out with double distilled water; the freeze-drying is preferably carried out by immersion in double distilled water; the freeze-drying temperature is preferably -60℃~-100℃, more preferably -70℃~-90℃, and more preferably -80℃, the pressure is preferably 0.0005~0.002mbar, more preferably 0.0008~0.0015mbar, and more preferably 0.001mbar; the freeze-drying time is preferably 1-5 days.

[0074] In a specific embodiment provided by the present invention, the phosphorylated modified methacryloyl gelatin is dissolved in double distilled water, and then an initiator solution is added and mixed evenly, and then a cross-linking agent is added and mixed, and then gelled at low temperature and freeze-dried to obtain a phosphoric acid-modified cryogel; the ratio of the phosphorylated modified methacryloyl gelatin to double distilled water is preferably 0.1 g: (5-15) mL, more preferably 0.1 g: (8-12) mL, and more preferably 0.1 g: (9.5-10) mL; the mass concentration of the initiator solution is preferably 5% to 15%, more preferably 8% to 12%, and more preferably 10%.

[0075] The phosphoric acid-modified cryogel and the mesoporous bioactive glass are co-incubated in an aqueous phase to obtain an antibacterial hemostatic material; the mass ratio of the phosphoric acid-modified cryogel to the mesoporous bioactive glass is preferably (1-10):1, more preferably (2-8):1, more preferably (2-5):1, more preferably (2-4):1, and most preferably 3:1; the mesoporous bioactive glass contains antibacterial metal ions and / or tannic acid; the antibacterial metal ions are metal ions with antibacterial properties well known to those skilled in the art, and there are no special restrictions. In the present invention, copper ions are preferably used; the co-incubation time is preferably 6-12 hours, and more preferably 8-12 hours.

[0076] In a specific embodiment provided by the present invention, mesoporous bioactive glass is ultrasonically dispersed in water, and then phosphoric acid-modified cryogel is added for co-incubation, and after freeze-drying, an antibacterial hemostatic material is obtained. The ratio of the mesoporous bioactive glass to water is preferably (0.1-1) mg:1 mL, more preferably (0.3-0.8) mg:1 mL, more preferably (0.4-0.6) mg:1 mL, and most preferably 0.5 mg:1 mL; the power of the ultrasonic dispersion is 100-300 W, more preferably 150-250 W, and more preferably 200 W; the time of ultrasonic dispersion is preferably 10-50 min, more preferably 20-40 min, and more preferably 25- 35min, most preferably 30min; the co-incubation time is preferably 6-12h, more preferably 8-12h; the freeze-drying temperature is preferably -60℃~-100℃, more preferably -70℃~-90℃, and more preferably -80℃; the pressure is preferably 0.0005~0.002mbar, more preferably 0.0008~0.0015mbar, and more preferably 0.001mbar; the freeze-drying time is preferably 2-4 days, more preferably 3 days.

[0077] In a specific embodiment provided by the present invention, the mesoporous bioactive glass is prepared according to the following method: A1) mixing antibacterial metal ions with ascorbic acid under heating conditions to obtain a metal / ascorbic acid mixed solution; A2) mixing a template solution with an organic solvent, then adding a precipitant and mixing, adding a silicon source, a calcium source and the metal / ascorbic acid mixed solution, reacting, drying, and calcining to obtain a metal ion-containing bioactive glass; A3) soaking the metal ion-containing bioactive glass in a tannic acid solution, and freeze-drying it to obtain a mesoporous bioactive glass.

[0078] In a specific embodiment provided by the present invention, the antibacterial metal ion is preferably a copper ion; the antibacterial metal ion is preferably provided by a soluble salt thereof; the molar ratio of the antibacterial metal ion to ascorbic acid is preferably 1:(1-4), more preferably 1:(2-4), further preferably 1:(2-3), and most preferably 1:2; specifically, an aqueous solution of the antibacterial metal ion and an ascorbic acid solution are mixed under heating conditions to obtain a metal / ascorbic acid mixed solution; further specifically, the aqueous solution of the antibacterial metal ion is heated, and then the ascorbic acid solution is added dropwise, heated and mixed, and centrifuged to obtain a metal / ascorbic acid mixed solution; the concentration of the antibacterial metal ion in the aqueous solution of the antibacterial metal ion is preferably The aqueous solution of antibacterial metal ions is preferably heated to 0.1-0.5 mol / L, more preferably 0.1-0.3 mol / L, and more preferably 0.2 mol / L; the temperature at which the aqueous solution of antibacterial metal ions is heated is preferably 70°C-90°C, more preferably 75°C-85°C, and more preferably 80°C; the heating time of the aqueous solution of antibacterial metal ions is preferably 40-80 min, more preferably 50-70 min, and more preferably 60 min; the temperature of the heating and mixing is preferably 70°C-90°C, more preferably 75°C-85°C, and more preferably 80°C; the heating and mixing time is preferably 20-30 h, more preferably 22-26 h, and more preferably 24 h; after centrifugation, the supernatant is taken to obtain a metal / ascorbic acid mixed solution, which is preferably stored at 4°C.

[0079] In a specific embodiment provided by the present invention, the template in the template solution is preferably a long-chain quaternary ammonium salt, more preferably cetyltrimethylammonium bromide (CTAB); the mass concentration of the template in the template solution is preferably 1% to 5%, more preferably 2% to 3%; the organic solvent is an organic solvent well known to those skilled in the art, without special restrictions, and is preferably ethyl acetate in the present invention; the volume of the organic solvent is preferably 0.01% to 0.05% of the volume of the template solution, more preferably 0.02% to 0.04%, and more preferably 0.03%; the mixing time of the template solution and the organic solvent is preferably 20 to 40 minutes, more preferably The precipitant is preferably a precipitant known to those skilled in the art without any particular limitation, and is preferably aqueous ammonia in the present invention; the concentration of aqueous ammonia is preferably 1-2 mol / L, more preferably 1 mol / L; the mixing time of adding the precipitant is preferably 10-20 min, more preferably 15 min; the silicon source is preferably an alkyl silicate, more preferably tetraethyl orthosilicate; the calcium source is preferably calcium nitrate; the molar ratio of the template, precipitant, silicon source and calcium source in the template solution is preferably (1-2): (4-8): (10-15): (10-15), more preferably (1-2): (5-6): (12-15): (1 1-14), more preferably (1-2):(5-6):(12-14):(11-13), most preferably 1.5:5.6:13:12; the molar ratio of the silicon source to the metal ions in the metal / ascorbic acid mixed solution is preferably (10-15):(0.5-1), more preferably (12-15):(0.5-1), more preferably (12-14):(0.5-1), more preferably 13:(0.5-1), most preferably 13:0.7; in the present invention, it is preferred to add the calcium source after a certain period of time after adding the silicon source, and the specific time interval between adding the silicon source and the calcium source is preferably 10-50 min, more preferably 20- 40min, more preferably 25-35min, most preferably 30min; the reaction time after adding the silicon source, calcium source and metal / ascorbic acid mixed solution is preferably 2-6h, more preferably 3-5h, and more preferably 4h; after the reaction, it is preferably centrifuged, and the precipitate is circulated and washed with double distilled water and anhydrous ethanol, and then dried and calcined; the drying temperature is preferably 50℃-80℃, more preferably 60℃-70℃; the calcination temperature is preferably 500℃-900℃, more preferably 600℃-800℃, more preferably 650℃-750℃, and most preferably 700℃; the calcination time is preferably 2-6h, more preferably 3-5h, and more preferably 4h.

[0080] In a specific embodiment provided by the present invention, the metal ion-containing bioactive glass is immersed in a tannic acid solution and freeze-dried to obtain the mesoporous bioactive glass; the mass concentration of tannic acid in the tannic acid solution is preferably 1% to 10%, more preferably 3% to 8%, more preferably 4% to 6%, and most preferably 5%; the soaking time is preferably 6 to 12 hours, more preferably 8 to 12 hours; the freeze-drying temperature is preferably -60°C to -100°C, more preferably -70°C to -90°C, and more preferably -80°C; the pressure is preferably 0.0005 to 0.002 mbar, more preferably 0.0008 to 0.0015 mbar, and more preferably 0.001 mbar; the freeze-drying time is preferably 1 to 5 days, more preferably 2 to 4 days, and more preferably 3 days.

[0081] The antibacterial hemostatic material prepared by the present invention is a low-temperature gel sponge containing cross-linked phosphate groups, which has porosity and can accommodate various components of blood. The material niche can provide adhesion sites for soluble and insoluble elements in the blood, including red blood cells, platelets and fibrinogen, and the sponge pore chamber contains abundant phosphate groups, which can provide adhesion positions to prevent blood flow; and as the concentration of various coagulation components in the material niche increases, it is conducive to promoting the occurrence of coagulation reaction, so that the antibacterial hemostatic material has significant hemostatic ability and antibacterial performance, can adhere to the damaged tissue of the bleeding wound, promote the formation of fibrin network, and thus shorten the bleeding time.

[0082] The present invention also provides an antibacterial hemostatic material prepared by the above preparation method. The antibacterial hemostatic material provided by the present invention has high porosity, can absorb blood at the bleeding wound to cover and seal the wound; at the same time, it relies on the tannic acid in the sponge to kill Staphylococcus aureus and Escherichia coli that may exist at the wound; and the antibacterial hemostatic material has high biocompatibility.

[0083] The present invention also provides an application of the antibacterial hemostatic material in preparing an antibacterial hemostatic sponge for application in a body wound to exert a hemostatic function.

[0084] In the present invention, unless otherwise specified, the water refers to deionized water or double distilled water.

[0085] In order to further illustrate the present invention, an antibacterial hemostatic material and a preparation method thereof provided by the present invention are described in detail below in conjunction with embodiments.

[0086] The reagents used in the following examples are all commercially available. The freezing strength of gelatin in the examples is 250 g bloom, and the pH value of the PBS solution is 7.4.

[0087] Example 1

[0088] Preparation of methacrylated gelatin: Accurately weigh 20g of gelatin powder using an electronic balance, and fully dissolve it in 200mL of PBS solution preheated to 60°C under stirring conditions (500rpm). Then, use a micropump to drop 16mL of methacrylated anhydride solution into the gelatin solution within 60 minutes in a dark environment, and the acylation reaction occurs under continuous stirring. Then add 600mL of PBS solution preheated to 60°C, stir and mix evenly, and filter the mixed solution with a 0.22μm filter after preparation. Put the filtered solution into a dialysis bag, seal the opening, and dialyze it in deionized water for 14 days (8000-14000Da) to remove unreacted compounds. Deionized water needs to be changed twice a day. After the dialyzed mixed solution is freeze-dried for 3 days, methacrylated gelatin (GelMA) is obtained.

[0089] Preparation of phosphoric acid-modified cryogel (GP): Take 100 mg of GelMA and fully dissolve it in 10 mL of deionized water to prepare a GelMA solution. Mix imidazole and carbonyl activation reagent (EDC hydrochloric acid) in water, then adjust the pH to 6, and adjust the pH to 6 after adding sodium hexametaphosphate. The molar ratio of imidazole to carboxyl activation reagent is 2.8:1; the molar ratio of imidazole to sodium hexametaphosphate is (13-14):1. React at room temperature for 2 hours, ethanol precipitation purification, -80°C, 0.001 mbar, and freeze-dry for 3 days to obtain imidazole-modified polyphosphate (PolyP-Im).

[0090] The PolyP-Im solution was added to the GelMA solution (the mass ratio of PolyP-Im to GelMA was 1:10) and stirred overnight at 50°C. The mixture was freeze-dried at -80°C, 0.001 mbar for 3 days to obtain phosphorylated modified GelMA cryogel (GP).

[0091] Add 100 mg of GP cryogel to 9.5 mL of ddH2O to prepare GP solution; then add 500 μL of 10% APS solution to the GP solution and mix well; then add 10 μL of TEMED (99%) to the mixture and shake it upside down. Transfer the mixture to a 48-well plate on ice and place it in a -20°C refrigerator for 24 hours for low-temperature gelation. Then thaw it at room temperature and rinse it three times with ddH2O to remove unreacted compounds. Since the hydrogel is easily damaged at this time, it needs to be rinsed gently. Then soak the GP hydrogel in ddH2O and freeze it at -80°C and 0.001 mbar for 3 days to obtain GP cryogel.

[0092] Preparation of bioactive glass containing tannic acid and copper ions: Dissolve CuCl2·2H2O in 50mL ddH2O to prepare a 0.2M CuCl2 solution; heat the CuCl2 solution to 80°C in an oil bath and add 50mL of 0.4M ascorbic acid solution dropwise after magnetic stirring for 1h. Stir the mixed solution at 80°C for 24h and centrifuge to obtain the supernatant, which is the copper / ascorbic acid mixture, and store it in a 4°C refrigerator.

[0093] Weigh 0.56g of hexadecyltrimethylammonium bromide (CTAB) and dissolve it in 26mL of ddH2O, and stir it evenly with magnetic stirring. After CTAB is completely dissolved, add 8μL of ethyl acetate solution and stir for 30min; add 5.6mL of 1M ammonia solution and stir for 15min; add 2.88mL of tetraethyl orthosilicate (TEOS) solution and 1.89g of calcium nitrate powder in sequence at intervals of 30min. Add 7mL of copper / ascorbic acid solution to the above mixture and stir for 4h; discard the supernatant after centrifugation, wash the precipitate with ddH2O and anhydrous ethanol for three times, and dry it at 60℃ overnight; the powder is calcined at 700℃ for 4h to obtain copper-doped bioactive glass nanoparticles (BG-Cu). BG-Cu was immersed in a 5% tannic acid solution overnight, and freeze-dried at -80°C and 0.001 mbar for 3 days to obtain tannic acid and copper ion bioactive glass (tannic acid-copper-doped bioactive glass nanoparticles, BG-Cu-TA).

[0094] Preparation of phosphate-modified cryogel containing bio-active glass loaded with copper ions and tannic acid: Weigh 2.5 mg BG-Cu-TA particles, dissolve in 5 mL ddH2O, and place in a 200W ultrasonic water bath at room temperature for 30 min. Soak the GP cryogel in it overnight, and freeze-dry at -80℃ and 0.001mbar to obtain phosphate-modified cryogel containing bio-active glass loaded with tannicacid and copper ions (GP@BG-Cu-TA).

[0095] Phosphoric acid-modified cryogel (GP@BG-TA) free of copper ion bioactive glass was prepared using this process.

[0096] The synthesis steps of phosphoric acid modified cryogel loaded with bioactive glass containing tannic acid and copper ions are as follows: Figure 1As shown, a is the GP synthesis equation, and b is the synthesis flow chart of GP@BG-Cu-TA cryogel. After introducing polyimidazole phosphate (PolyP-Im) into the GelMA solution, phosphorylation modification is achieved, and then the cross-linking agents ammonium persulfate (APS) and tetramethylethylenediamine (TEMED) are added, and then placed in a -20°C environment for low-temperature gelation. In the semi-frozen state in the low-temperature environment, when gelation begins to form ice crystals, the polymer and the cross-linker will react and combine with each other. During freeze-drying, the ice crystals acting as pore formers will vaporize, thereby forming a cryogel with a large pore size and interconnected pore structure. The cryogel is then added to water containing 2.5 mg / mL bioactive glass and incubated together so that the bioactive glass is loaded onto the cryogel surface in the form of ionic bonds. After freeze-drying, GP@BG-Cu-TA cryogel is obtained, as shown in the photo. Figure 2 shown.

[0097] The morphology and structure of bioactive glass Figure 3 As shown, a is a photo of bioactive glass, b is a transmission electron microscope TEM photo of bioactive glass, and c is a scanning electron microscope SEM photo of bioactive glass. Figure 3 As can be seen in a, the bioactive glass prepared by calcination is an off-white powder. After combining with copper ions, the particles appear blue, while after combining with tannic acid, the particles appear yellow. The size and structure of the bioactive glass were evaluated by TEM and SEM. Figure 3 As can be seen from b and c, the four groups of bioactive glasses are all regular spherical in shape, with similar shapes and sizes and uniform diameters. As shown in the figure, the diameters of each group are mainly distributed between 80 and 100 nm, BG is 90.60±6.45 nm, BG-Cu is 81.20±9.71 nm, BG-TA is 85.47±11.56 nm, and BG-Cu-TA is 85.32±9.71 nm.

[0098] Morphology and structure of GP@BG-Cu-TA cryogel: Figure 2 It can be seen that the pure GelMA cryogel is white in appearance and hard in texture, the GP cryogel is white in appearance and soft in texture, and after the bioactive glass containing tannic acid groups and copper ions is loaded into the cryogel, the color of the cryogel changes from white to light yellow. The structure of each type of cryogel and the surface binding of bioactive glass were evaluated by SEM, and the results were observed at 200 times, 500 times and 5000 times magnification respectively. Figure 4As shown. It can be seen that the characteristic structure of cryogel can be used to absorb blood. This loose large-pore spatial structure can expand the contact area between blood cells and materials. When GelMA and GP were observed at 5000 times the diameter, the surface of the cryogel was smooth and flat, without any particles attached; bioactive glass was observed to be attached to the surface of both the GP@BG-TA group and the GP@BG-Cu-TA group (indicated by white arrows), which indicates that the bioactive glass has been successfully loaded into the cryogel system, and also indicates that the bioactive glass combined with tannic acid has not changed its properties and can be attached to the cryogel surface as expected.

[0099] Using nuclear magnetic resonance (NMR) spectroscopy, hydrogen and phosphorus spectroscopy ( 1 H and 31 P) evaluate the effect of polyimidazole phosphate (PolyP-Im) on cryogel properties, and obtain the nuclear magnetic resonance spectrum of GP cryogel as shown in Figure 5 As shown. From the results, it can be seen that GP has a strong Figure 5 In the middle a), obvious characteristic peaks appeared at 2.2ppm, -7.4ppm and -21.4ppm, while in the hydrogen spectrum ( Figure 5 In b), obvious characteristic peaks also appeared at 2.7 ppm, 7.1 ppm and 7.9 ppm, indicating that PolyP-Im introduced phosphate and hydrogen ion groups into GelMA, confirming the success of the modification.

[0100] The water absorption performance of GP@BG-Cu-TA cryogel was tested, and the swelling rate curve of GP@BG-Cu-TA was obtained as shown in the figure. Figure 6 As shown (Note: **p<0.01). The swelling rate is an important physical property of cryogel, which reflects its ability to absorb liquid and determines whether it is suitable to serve as a hemostatic dressing for clinical services. The present invention uses pH=7.4, PBS solution as the measuring medium, pre-weighs GP@BG-Cu-TA and GelMA, and then puts them into PBS at the same time. At 1, 2, 3, 4, 5, 10, and 15 minutes, the materials are taken out and weighed for wet weight. After subtracting the dry weight, the weight of the liquid absorbed by the material is obtained. The ratio of the increased weight to the dry weight is the swelling rate (Swelling ratio). Figure 6As shown in the figure, the swelling rate of GP@BG-Cu-TA after phosphorylation modification is significantly improved, and the swelling rate at 15 minutes reaches 39.91±2.25%. It can absorb up to 40 times its own weight of liquid, which is statistically significant compared with the swelling rate of 29.48±1.62% of GelMA. In addition, the swelling rate of GP@BG-Cu-TA cryogel is 38.76±0.76% at 60 seconds, which is close to the maximum swelling rate, indicating that it can quickly absorb liquid and reach the maximum equilibrium state. The results show that GP@BG-Cu-TA cryogel has an advantage in absorbing liquid volume compared to GelMA.

[0101] Porosity of GP@BG-Cu-TA cryogel: Porosity refers to the proportion of vacuolar space in a solid volume. The greater the porosity, the greater the proportion of pores in the material. First, anhydrous ethanol was used as the measurement medium to obtain the porosity test results of each group of cryogels. Figure 7 As shown in the figure (Note: ***p<0.001, ns indicates no statistical difference), the porosity of GelMA, GP, GP@BG-TA, and GP@BG-Cu-TA are 55.49±0.014%, 77.77±0.012%, 76.58±0.009%, and 77.95±0.001%, respectively. After modification with polyimidazole phosphate, the porosity of the cryogel is significantly higher than that of GelMA, indicating that the introduction of phosphate groups successfully increases the pore structure of the cryogel and improves its liquid absorption capacity. In addition, statistical analysis shows that there is no statistical difference between the three groups of cryogels of GP, GP@BG-TA, and GP@BG-Cu-TA, indicating that the addition of bioactive glass will not reduce the porosity of the cryogel.

[0102] Biodegradation study of cryogel: In order to confirm the sensitivity of GP@BG-Cu-TA to enzymatic degradation, the present invention used an in vitro experiment based on collagenase I to evaluate the degradation of cryogel by residual mass, and the degradation rate of cryogel was obtained as shown in the figure. Figure 8 As shown in the figure, within 2 weeks, all cryogels were completely degraded, which was achieved on the basis that GelMA would be rapidly degraded in the presence of biological enzymes. This suggests that GP@BG-Cu-TA has excellent enzymatic hydrolysis performance and can be used in subsequent in vitro cell culture and in vivo hemostasis experiments.

[0103] Cytocompatibility of GP@BG-Cu-TA: The effect of GP@BG-Cu-TA on the growth of mouse fibroblast cell line NIH3T3 cells was studied using live-dead staining. After culturing NIH3T3 cells with GelMA, GP, GP@BG-TA and GP@BG-Cu-TA material extracts for 72 hours, live-dead staining was performed using phalloidin dye labeled with a green fluorescent probe. Live-dead staining images of each treatment group and quantitative images of NIH3T3 live cell proliferation were obtained as shown in the figure below. Fig. 9 As shown (ns means no statistical difference). Fig. 9 As shown in a, the cell morphology of each group showed normal morphology, the cells adhered to the well plate, were in good condition, and the number did not decrease significantly. There were a large number of green-labeled live cells and no red-labeled dead cells, which indicated that GP@BG-Cu-TA cryogel would not cause cell apoptosis and had good cell compatibility. Secondly, NIH3T3 cells were cultured with the material leaching solution, and the effect of GP@BG-Cu-TA on cell proliferation was further quantitatively studied. Based on the fluorescence photos, the total fluorescence intensity (Integrated Density, IntDen) of each group was analyzed using Image J software, as shown in Figure 1. Fig. 9 As shown in the statistical results in middle b, with the increase of time, the total immunofluorescence intensity of each treatment group increased normally, and there was no statistical significance compared with the Control group, which indicates that GP@BG-Cu-TA will not have toxic side effects on cells.

[0104] like Fig.10 As shown, the cell compatibility of GP@BG-Cu-TA was further studied. Fig.10 The figure shows the effect of the material leaching solution on the proliferation ability of NIH3T3 cells (Note: ns means no statistical difference). Fig.10 It can be seen that the proliferation efficiency of NIH3T3 cells was evaluated by CCK-8 method at 24 hours, 72 hours and 120 hours of co-culture with NIH3T3 cells. There was no statistical difference between the GP@BG-Cu-TA group and the Control group after statistical comparison. The above proves that the GP@BG-Cu-TA group has no effect on cell proliferation activity, cells can proliferate normally, cells maintain normal morphology, and no adverse phenomenon of regional death occurs.

[0105] In vitro antibacterial properties of cryogels: To investigate the antibacterial properties of tannic acid-containing bioactive glass, Staphylococcus aureus (Sa), representing Gram-positive bacteria, and Escherichia coli (Ec), representing Gram-negative bacteria, were co-cultured with each cryogel in a 37°C bacterial incubator for 12 hours. The material was then rinsed with PBS to collect any bacteria that might be present. For subsequent counting, the collected PBS containing bacteria was diluted in the same proportion and applied to a sterile LB solid culture dish. After culturing for 24 hours, the colonies were marked and counted, and the colony photos of the agarose bacterial culture dishes coated with each group of cryogels after co-culture and the quantitative graphs of the colony numbers were obtained as shown in the figure below. Fig.11 As shown (Note: ***p<0.001). Fig.11 As shown in a, no bacterial colonies grew in the culture dishes of the GP@BG-TA and GP@BG-Cu-TA groups. Fig.11 Figure b is the statistics of colony counts, and the calculated antibacterial rates of GP@BG-TA and GP@BG-Cu-TA are both over 99%, which reveals the strong antibacterial ability of tannic acid.

[0106] In vivo antibacterial repair of skin by cryogel: To further verify the antibacterial ability of the material, the present invention established a mouse full-thickness wound model. A 6mm circular defect was made at 0.5cm from the side of the spine on the back of the mouse using a puncher. Then, a common skin bacterium, Staphylococcus aureus, was added to simulate the recovery process of a bacterial wound. The full-thickness wound healing was obtained as shown in the following figure. Fig.12 As shown. During the recovery process, it was found that even though the mice had amazing self-healing ability, the control group without any treatment still found pus exudation at the wound on the second day after surgery, but the pus was absorbed on the fifth day, and its recovery speed was slower than that of the GP, GP@BG-TA and GP@BG-Cu-TA treatment groups. Considering the excellent liquid absorption capacity of the cryogel, the bacterial liquid at the wound was absorbed, which reduced the bacterial load in the wound and increased the healing speed.

[0107] Image J software was used to analyze the wound area and obtain the statistical analysis of full-thickness healing. Fig.13 As shown, a is the digital superposition of the injured area and the healing area of ​​each group, and b is the wound area of ​​each treatment group. (Note: ***p<0.001). Fig.13 (a) shows the wound healing status by overlapping the 0th day, the 7th day and the 14th day. Fig.13In (b), the ratio of wound area to the initial area on day 0 was used to replace the wound healing rate. The larger the wound damage area, the lower the healing rate. The wound area on day 0 was set as 100%. The three groups using highly water-absorbent phosphoric acid-modified GP, GP@BG-TA and GP@BG-Cu-TA had residual wound areas of 0.93±0.35%, 1.08±0.33% and 1.51±0.35% on day 14, respectively, compared with 3.84±1.49% in the control group, all of which showed excellent wound healing rates, with statistically significant differences.

[0108] In vitro whole blood coagulation index of GP cryogel loaded with tannic acid and copper ion bioglass: The blood clotting index (BCI) is used to evaluate the coagulation effect of cryogel materials. The free red blood cells that have not coagulated into blocks will swell and rupture in water due to osmotic pressure and tension, releasing hemoglobin into the water, affecting the absorbance of the solution, thereby quantitatively analyzing the ability of each cryogel to absorb and adhere to red blood cells. The cryogel in vitro coagulation index test results are shown in the figure below. Fig.14 As shown, a is a digital photo of the interaction between cryogel and blood, and b is the BCI index of each cryogel group (Note: ***p<0.001). Fig.14 (a) shows digital photos of each cryogel immersed in water after absorbing blood. In the Blank group, red blood cells completely ruptured in the water and the liquid appeared red, while the other groups of cryogels all adsorbed red blood cells inside the material. The color of the supernatant in the GelMA group was slightly lighter than that in the Blank group, and the color of the supernatant in the GP@BG-Cu-TA group was second. It can be concluded that GP@BG-Cu-TA has the strongest blood adsorption capacity. Fig.14 (b) shows the absorbance of the supernatant of each group at 541 nm. At 150 s, the groups were 85.11±1.45% for Blank group, 40.9±1.69% for GelMA group, 18.74±1.99% for GP group, 9.47±0.28% for GP@BG-TA group, and 7.01±0.99% for GP@BG-Cu-TA group. The BCI index of GP@BG-Cu-TA group was the lowest, which means that this group absorbed the most red blood cells in the same time and showed excellent ability to adhere to red blood cells.

[0109] Hemostatic properties of rat liver loaded with GP cryogel containing tannic acid and copper ion bioglass Fig.15 As shown, Fig.15 Schematic diagram of hemostasis in rat liver injury model, statistical results of bleeding volume and bleeding time in each treatment group (Note: ***p<0.001): Establishment of rat liver injury model Fig.15(a) A 1 cm long and 0.5 cm deep incision was made on the liver surface with a surgical blade, and then each group of cryogels was immediately covered and the bleeding time and amount were recorded. Fig.15 As shown in (b, c), the bleeding volume and bleeding time of each group were 812.83±177.28mg and 316.17±55.89s in the Control group, 152.17±20.23mg and 152.17±20.23s in the GelMA group, 184.0±36.45mg and 67.67±18.94s in the GP group, 161.83±27.82mg and 66.0±14.90s in the GP@BG-TA group, and 156.17±44.64mg and 65.83±18.15s in the GP@BG-Cu-TA group. Compared with the Control group, after applying GP@BG-Cu-TA, the bleeding volume was reduced by 5 times and the bleeding time was reduced by 4 times, proving that it has an in vivo hemostatic effect on bleeding.

[0110] In order to evaluate the in vivo safety of the material, after using the material to stop bleeding, the abdominal cavity was closed with surgical sutures, and the rats were killed on the 21st day after surgery. The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and urea nitrogen (BUN) in the serum were detected using Elisa kits, as shown in Figure 2. Fig.16 As shown in (a-c), a is the aspartate aminotransferase content of each treatment group, b is the alanine aminotransferase content of each treatment group, and c is the urea nitrogen content of each treatment group (Note: ns means no statistical significance). There was no statistical difference in the indicators of each material group. The heart, liver, spleen, lung, and kidney were taken for histological pathological examination. The results of HE staining of the histopathological sections are shown in Fig.16 As shown in (d), no significant inflammatory cell infiltration and tissue structural changes were found. The above results fully prove the in vivo compatibility of the material and can be applied to traumatic bleeding.

[0111] In summary, the present invention uses phosphate groups to modify GelMA cryogel for the first time, changing its properties and improving its physical properties. Compared with GelMA cryogel, the improved cryogel has better liquid absorption capacity, excellent antibacterial ability and excellent biocompatibility.

[0112] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing an antibacterial hemostatic material, It is characterized in that The following steps are involved: S1) reacting phosphate with a nitrogen-containing heterocyclic compound in the presence of a coupling agent to obtain a polyphosphoric acid substance containing a nitrogen-containing heterocyclic ring; S2) mixing the polyphosphoric acid substance containing nitrogen-containing heterocycles with methacryloyl gelatin to obtain phosphorylated modified methacryloyl gelatin; S3) mixing the phosphorylated modified methacryloyl gelatin, an initiator and a cross-linking agent in water, gelling at low temperature, and freeze-drying to obtain a phosphoric acid-modified cryogel; S4) co-incubating the phosphoric acid-modified cryogel with mesoporous bioactive glass in an aqueous phase to obtain an antibacterial hemostatic material; the mesoporous bioactive glass contains antibacterial metal ions and / or tannic acid.

2. The preparation method according to claim 1, It is characterized in that The mesoporous bioactive glass is prepared according to the following method: A1) mixing an antibacterial metal ion with ascorbic acid under heating to obtain a metal / ascorbic acid mixed solution; A2) mixing the template solution with an organic solvent, then adding a precipitant and mixing, and then adding a silicon source, a calcium source and a metal / ascorbic acid mixed solution, reacting, drying, and calcining to obtain a metal ion-containing bioactive glass; A3) Soaking the metal ion-containing bioactive glass in a tannic acid solution and freeze-drying the solution to obtain the mesoporous bioactive glass.

3. The preparation method according to claim 2, It is characterized in that The metal ions with antibacterial properties are selected from copper ions; The template in the template solution is selected from long-chain quaternary ammonium salts; The organic solvent is selected from ethyl acetate; The precipitant is selected from ammonia water; The silicon source is selected from alkyl silicates; The calcium source is selected from calcium nitrate.

4. The preparation method according to claim 2, It is characterized in that The molar ratio of the antibacterial metal ion to ascorbic acid is 1:(1-4); The volume of the organic solvent is 0.01% to 0.05% of the volume of the template solution; The molar ratio of the template, the precipitant, the silicon source and the calcium source in the template solution is (1-2): (4-8): (10-15): (10-15); The molar ratio of the silicon source to the metal ions in the metal / ascorbic acid mixed solution is (10-15): (0.5-1); The mass concentration of tannic acid in the tannic acid solution is 1% to 10%.

5. The preparation method according to claim 2, It is characterized in that The step A1) is specifically as follows: heating an aqueous solution of metal ions with antibacterial properties, then dropping an ascorbic acid solution, heating and mixing, and centrifuging to obtain a metal / ascorbic acid mixed solution; the temperatures of the heating and heating mixing are independently 70°C to 90°C; and the heating and mixing time is 20 to 30 hours.

6. The preparation method according to claim 2, It is characterized in that The time for mixing the template solution and the organic solvent in step A2) is 20 to 40 minutes; The mixing time of adding precipitant is 10 to 20 minutes; The interval between adding silicon source and calcium source is 10 to 50 minutes; The reaction time is 2 to 6 hours; The calcination temperature is 500°C to 900°C; the calcination time is 2 to 6 hours; The soaking time in step A3) is 6 to 12 hours.

7. The preparation method according to claim 1, It is characterized in that The phosphate is selected from sodium hexametaphosphate; The nitrogen-containing heterocyclic compound is selected from imidazole; The molar ratio of the phosphate to the nitrogen-containing heterocyclic compound is (8-20):1; The mass ratio of the polyphosphoric acid substance containing nitrogen-containing heterocyclic ring to the methacrylated gelatin is 1:(5-15); The initiator is selected from ammonium persulfate and / or potassium persulfate; The cross-linking agent is selected from tetramethylethylenediamine; The temperature of the low-temperature gelling is -10°C to -30°C; the time of the low-temperature gelling is 15 to 30 hours; The freeze-drying temperature in step S3) is -60°C to -100°C, the pressure is 0.0005 to 0.002 mbar, and the time is 1 to 5 days.

8. The preparation method according to claim 1, It is characterized in that The step S4) is specifically as follows: ultrasonically dispersing the mesoporous bioactive glass in water, then adding the phosphoric acid-modified cryogel for co-incubation, and freeze-drying to obtain the antibacterial hemostatic material.

9. The preparation method according to claim 8, It is characterized in that In step S4), the ratio of the mesoporous bioactive glass to water is (0.1-1) mg:1 mL; The power of ultrasonic dispersion in step S4) is 100-300W; the time of ultrasonic dispersion is 10-50min; The co-incubation time is 6 to 12 hours; The freeze-drying temperature in step S4) is -60°C to -100°C, the pressure is 0.0005 to 0.002 mbar, and the time is 1 to 5 days.

10. An antibacterial hemostatic material prepared by the preparation method according to any one of claims 1 to 9.